Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Sep 30;10(1):1–11. doi: 10.20411/pai.v10i1.752

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2024 Pathogens and Immunity

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

PMC Copyright notice

Figure 2. — Neutralization of SARS-CoV-2 variants circulating in mid-2024 by mAbs. A. Neutralization curves of mAbs in S-Fuse cells. Dose-response analysis of neutralization of the indicated variants by S309/Sotrovimab, VYD222/Pemivibart, AZD3152/Sipavibart, and SA55. Data are presented as mean ± standard deviation of 2–3 independent experiments. B. Neutralization curves of mAbs in IGROV-1 cells. Dose-response analysis of neutralization of the indicated variants by S309/Sotrovimab, VYD222/Pemivibart, AZD3152/Sipavibart, and SA55. Data are presented as mean ± standard deviation of 2–3 independent experiments. C. EC50 values (in ng/mL) for each mAb against the indicated viral strains in the 2 cell lines. “- ”: no antiviral activity.